Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
The study seeks to provide long-term follow-up and/or to offer continued maintenance
thalidomide (THALOMID) therapy to those patients enrolled in 20030165. Patients will be
followed until withdrawal of consent, or death.
Phase
Phase 2
Funding Agency/Sponsor
Institutional
Disease
Lymphoma
Enrollment Eligibility
Inclusion Criteria:
1. Enrolled on the 20030165 clinical trial.
2. Ability to understand and willingness to sign a written informed consent document.
Exclusion Criteria:
1. Patients who were discontinued from 20030165 for any reason prior to the completion of
protocol-specified treatment (e.g. withdrawal of consent).
2. Uncontrolled, intercurrent serious illness including but not limited to ongoing or
active infection, symptomatic congestive heart failure, unstable angina pectoris,
and/or cardiac arrhythmia likely in the judgment of the PI to interfere with clinical
study requirements.
3. Psychiatric illness/condition likely in the judgment of the PI to limit compliance
with clinical study requirements.